Eculizumab exposure in generalized myasthenia gravis
A two-compartment PK model representing eculizumab central and peripheral disposition and cumulative exposure in generalized myasthenia gravis.
- Therapeutic
- Eculizumab
- Target
- Complement C5
- Disease
- Generalized myasthenia gravis
Biological model
A two-compartment PK model representing eculizumab central and peripheral disposition and cumulative exposure in generalized myasthenia gravis.
Intervention
Eculizumab
Biological focus
Complement C5
Context
Generalized myasthenia gravis
Model details
A two-compartment PK model representing eculizumab central and peripheral disposition and cumulative exposure in generalized myasthenia gravis.
Modeled states
- AUC ug h mLug*hour/mL
Modeled dynamic state for auc ug h ml.
- central mgmg
Modeled dynamic state for central mg.
- elapsed time hhour
Modeled dynamic state for elapsed time h.
- peripheral mgmg
Modeled dynamic state for peripheral mg.
Key readouts
- Central eculizumab concentrationunknown
Model-derived readout for central eculizumab concentration.
- Peripheral eculizumab concentrationunknown
Model-derived readout for peripheral eculizumab concentration.
- Cumulative eculizumab exposureug*hour/mL
Model-derived readout for cumulative eculizumab exposure.
- central mgmg
Model-derived readout for central mg.
- elapsed time hhour
Model-derived readout for elapsed time h.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
REGAIN approved 900/1200 mg IV regimen PK/PD context
How does the eculizumab regimen determine concentration and cumulative exposure over time? Explore this intervention regimen through Central eculizumab concentration, Peripheral eculizumab concentration, Cumulative eculizumab exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How does the eculizumab regimen determine concentration and cumulative exposure over time?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How does the eculizumab regimen determine concentration and cumulative exposure over time?
CL L h
Model parameter controlling cl l h.
Exploratory range around the default value.
5 evenly spaced values in L/h. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia GravisFrontiers in Neurology
